Nuvectis Pharma (NVCT) Net Income towards Common Stockholders (2021 - 2026)

Nuvectis Pharma has reported Net Income towards Common Stockholders for 6 years, with the latest figure at -$6.0 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 13.47% year-over-year to -$6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$29.6 million (down 46.76% YoY) and the FY2025 annual result came in at -$28.9 million, down 51.95% from the prior year.
• Net Income towards Common Stockholders improved to -$6.0 million in Q1 2026 per NVCT's latest filing, from -$7.3 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$2.9 million in Q1 2022 and troughed at -$9.9 million in Q3 2025.
• A 5-year average of -$5.6 million and a median of -$5.9 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• The widest YoY moves for Net Income towards Common Stockholders: up 39.9% in 2022, down 196.15% in 2022.
• Over 5 years, Net Income towards Common Stockholders stood at -$6.7 million in 2022, then climbed by 1.11% to -$6.6 million in 2023, then rose by 5.65% to -$6.2 million in 2024, then dropped by 17.06% to -$7.3 million in 2025, then gained by 17.28% to -$6.0 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$6.0 million, -$7.3 million, and -$9.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.